In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services.
On Saturday, Dec. 21, Congress passed a new spending package, narrowly averting a government shutdown.
Robert F. Kennedy Jr., President-elect Donald Trump’s choice for HHS secretary, is unfit for that role and should not be confirmed, 77 Nobel laureates said in a letter to members of the U.S. Senate.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
The Senate Appropriations Committee voted to provide significant increases to federal health agencies in fiscal year 2025, including raises of nearly $2 billion for NIH and $270 million for NCI.
Two Republican leaders in the House of Representatives have published a “framework” for reforming NIH—consolidating the agency’s 27 institutes and centers into 15—arguing that a fundamental rethinking of NIH’s structure would fix what they describe as a “system rife with stagnant leadership, as well as research duplication, gaps, and misconduct.”
NCI Director Kimryn Rathmell joined the NIH director and four other institute directors in a May 23 Senate subcommittee hearing to craft the Labor-HHS spending bill for fiscal year 2025.
Sen. Richard J. Durbin (D-IL) has asked Amgen to provide copies of the company’s communications with FDA related to the dosage of Lumakras (sotorasib), a KRAS inhibitor marketed under an accelerated approval for non-small cell lung cancer.
Credit: National Cancer Institute, National Institutes of HealthHalfway into fiscal year 2024, NCI officials are crunching numbers, trying to find ways to live with an appropriation that, for the first time since sequestration, reduces the institute’s spending power.
As NCI continues to hobble along on a flat budget provided by a succession of continuing resolutions, the prospects for robust funding for cancer research, rising paylines, and healthy cancer center support grants have dimmed for this fiscal year. “The extended delay in passing the FY2024 budget is disastrous for our cancer centers,” Jennifer W.... […]
